Expanded Access

• Expanded Access provides a pathway for patients with serious conditions to access investigational drugs before full FDA approval.
• It is considered when patients have exhausted all other treatment options and cannot participate in a clinical trial.
• The process involves a request from the treating physician, agreement from the drug manufacturer, and authorization from the FDA.
• Eligibility criteria are strict, focusing on patient need, potential benefit, and safety considerations.
• Expanded Access is not a guarantee and is intended as a last resort, balancing patient hope with regulatory oversight.

What is Expanded Access?

What is Expanded Access refers to the use of an investigational drug, biologic, or medical device for a patient with a serious or immediately life-threatening disease or condition who is not eligible to participate in a clinical trial. This pathway is designed for situations where there are no other satisfactory treatment options available. It provides a potential lifeline for patients facing severe illnesses, offering access to therapies that are still undergoing clinical investigation and are not yet approved for general use by regulatory bodies like the U.S. Food and Drug Administration (FDA).

The primary goal of what is expanded access to drugs is to provide individual patients with access to promising therapies when their medical needs are urgent and unmet. It is distinct from clinical trials, which are primarily designed to gather data on a drug’s safety and efficacy. While some data may be collected during expanded access, its main purpose is patient treatment. The FDA plays a crucial role in reviewing and authorizing these requests, ensuring that potential benefits outweigh risks and that patient safety remains a priority.

How Expanded Access Works

Understanding how does expanded access work involves a multi-step process initiated by a patient’s treating physician. The physician first determines if the patient meets specific criteria, such as having a serious or life-threatening condition, having exhausted all approved treatment options, and being unable to enroll in a clinical trial. If these conditions are met, the physician then contacts the drug manufacturer to request access to the investigational product. The manufacturer must agree to provide the drug, often considering factors like drug supply, manufacturing capacity, and their own internal policies.

Once the manufacturer agrees, the physician must submit an Expanded Access Investigational New Drug (IND) application to the FDA. This application includes information about the patient’s condition, the proposed treatment plan, and the potential risks and benefits of the investigational drug. The FDA reviews these applications expeditiously, often within days for emergency cases, to ensure that the patient’s safety is protected and that the use of the investigational product is ethically justifiable. According to FDA data, the agency authorizes over 99% of expanded access requests, demonstrating a commitment to facilitating access while maintaining regulatory oversight.

There are generally three categories of expanded access, depending on the scope of the request:

• Individual Patient Expanded Access: For a single patient, typically when immediate treatment is needed.
• Intermediate-Size Patient Population Expanded Access: For a group of patients who do not meet the criteria for a clinical trial but have a common serious or life-threatening condition.
• Treatment IND or Treatment Protocol: For widespread use of an investigational drug in a large patient population, typically for serious conditions where the drug shows promise.

Eligibility & Patient Access

Gaining expanded access for patients is subject to stringent criteria designed to protect patient safety while providing potential treatment. Patients must have a serious or immediately life-threatening disease or condition, and there must be no comparable or satisfactory alternative therapy available. Furthermore, the potential benefit to the patient must justify the potential risks of the investigational drug, and providing the drug should not interfere with ongoing clinical trials that could lead to the drug’s approval for a broader population.

The expanded access program requirements also involve the drug manufacturer and the treating physician. The manufacturer must be willing and able to provide the investigational drug, and the physician must be qualified to administer the treatment and monitor the patient for adverse effects. An Institutional Review Board (IRB) must also review and approve the expanded access protocol to ensure ethical considerations are met and patient rights are protected. This multi-layered approval process underscores the gravity of using unapproved therapies and the commitment to patient well-being.